Fourth Quarter – Elizabeth Holmes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
For the Year Ended December 31, 2010 (Ninety-First Edition)
State of Delaware Office of the State Bank Commissioner Annual Report For the Year Ended December 31, 2010 (Ninety-first Edition) Robert A. Glen Commissioner The Honorable Jack A. Markell Governor of the State of Delaware Tatnall Building Dover, Delaware 19901 Dear Governor Markell: I have the honor of presenting the 91st Annual Report of the State Bank Commissioner for the year ending December 31, 2010. This annual report includes the highlights for 2010, and an overview of our work in maintaining a strong financial services industry and protecting consumers. Detailed financial information about Delaware banks, trust companies, and building and loan associations is included in this report, together with tables, charts and graphs that show the strength of the banking industry in our State. The report also includes information regarding the non-bank businesses and individuals we license to provide financial services to consumers in Delaware. Respectfully submitted, Robert A. Glen State Bank Commissioner TABLE OF CONTENTS Page Year 2010 Highlights 1 Overview of the Office of the State Bank Commissioner Approving Bank and Trust Company Applications 2 Examining Financial Institutions 2 Administering the Bank Franchise Tax 3 Licensing Non-Depository Institutions 3 Licensing Individual Mortgage Loan Originators 4 Responding to Consumer Questions and Complaints 4 Providing Consumer Education 4 The State Banking Code and Regulations The State Banking Code 5 State Bank Commissioner Regulations 5 Organizational Chart 6 State Bank Commissioners 7 Council on Banking 8 Banks, Trust Companies, and Building and Loan Associations Bank and Trust Company Changes 9 Number of Type of Institutions 2009 vs. 2010 11 Assets and Income 2006 – 2010 12 Assets 2006-2010 13 Income 2006-2010 14 Delaware Bank Employees 1987 – 2010 15 Bank Franchise Tax Collections by Fiscal Year 16 List of Institutions 17 Financial Statements of Institutions 20 Edge Act Corporations Located in Delaware 104 Licensed Non-Depository Financial Institutions Number of Non-Depository Institutions 2009 vs. -
Theranos As a Legal Ethics Case Study
Vanderbilt University Law School Scholarship@Vanderbilt Law Vanderbilt Law School Faculty Publications Faculty Scholarship 2021 How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study G. S. Hans Follow this and additional works at: https://scholarship.law.vanderbilt.edu/faculty-publications Part of the Legal Education Commons, and the Legal Ethics and Professional Responsibility Commons DATE DOWNLOADED: Mon May 24 12:25:08 2021 SOURCE: Content Downloaded from HeinOnline Citations: Bluebook 21st ed. G. S. Hans, How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study, 37 GA. St. U. L. REV. 427 (2021). ALWD 6th ed. Hans, G. G., How and why did it go so wrong?: Theranos as a legal ethics case study, 37(2) Ga. St. U. L. Rev. 427 (2021). APA 7th ed. Hans, G. G. (2021). How and why did it go so wrong?: Theranos as legal ethics case study. Georgia State University Law Review, 37(2), 427-470. Chicago 17th ed. G. S. Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study," Georgia State University Law Review 37, no. 2 (Winter 2021): 427-470 McGill Guide 9th ed. G S Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study" (2021) 37:2 Ga St U L Rev 427. AGLC 4th ed. G S Hans, 'How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study' (2021) 37(2) Georgia State University Law Review 427. MLA 8th ed. -
The Effect of FOMO on Stakeholder Enrollment
The Effect of FOMO on Stakeholder Enrollment Susan L. Young, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-4536 [email protected] Birton Cowden, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-36781 [email protected] 1 The Effect of FOMO on Stakeholder Enrollment Abstract Stakeholder theory suggests dishonest ventures would struggle with stakeholder enrollment, limiting resource access and ultimately failing. Yet cases exist where amoral entrepreneurs do enroll stakeholders through deceit. We propose “fear of missing out” on an opportunity facilitates enrollment by encouraging stakeholder acceptance of information asymmetry. To illustrate we use exemplar Theranos: a biotech firm which convinced stakeholders it would revolutionize healthcare, rising to a $10 billion valuation through 15 years of sustained deceit. We contribute to theory by demonstrating the dark side of stakeholder enrollment, where opportunism increases venture power over stakeholders, and deceit can endure long past start up. Keywords: stakeholder theory, stakeholder enrollment, entrepreneurial deceit, fear of missing out, legitimacy 2 The Effect of FOMO on Stakeholder Enrollment “Theranos had demonstrated a commitment to investing in and developing technologies that can make a difference in people’s lives, including for the severely wounded and ill. I had quickly seen tremendous potential in the technologies Theranos develops, and I have the greatest respect for the company’s mission and integrity.” (Johnson, 2015) — 4-star General Jim Mattis, U.S. Marine Corps, Retired U.S. Secretary of Defense, 2017-2019 The Securities and Exchange Commission today charged Silicon Valley-based private company Theranos Inc., its founder and CEO Elizabeth Holmes, and its former President Ramesh “Sunny” Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about the company’s technology, business, and financial performance. -
Downloads/Aib Provincial Wait Times E.Pdf; 18, 2006)
Committee for Economic Development Comm 2000 L Street N.W., Suite 700 A StatementStatement bbyy tthehe Washington, D.C. 20036 RResearchesearch aandnd PPolicyolicy 202-296-5860 Main Number 202-223-0776 Fax CCommitteeommittee ooff tthehe 1-800-676-7353 CCommitteeommittee fforor EEconomicconomic DDevelopmentevelopment www.ced.org A Statement by the Research and Policy Committee of the Committee for Economic Development i Quality, Aff ordable Health Care for All Moving Beyond the Employer-Based Health-Insurance System Includes bibliographic references ISBN #0-87186-187-9 First printing in bound-book form: 2007 Printed in the United States of America COMMITTEE FOR ECONOMIC DEVELOPMENT 2000 L Street, N.W., Suite 700 Washington, D.C., 20036 202-296-5860 www.ced.org Contents Purpose of Th is Statement . xi Executive Summary . 1 I. Introduction. 9 Why Another CED Statement on Health Care?. 9 Is the U.S. Health-Care System Failing? Performance Standards for a Nation’s Health-Care System . 10 Does the American Health-Care System Meet Th ese Standards? . 11 Why Is Employer-Based Health Insurance Declining?. 12 Th e Causes of High and Rising National Health Expenditures . 12 EBI Costs Cause Major Problems for Employers . 14 Employer Responses to Date Have Not Solved the Problem . 15 Buyers Cannot Hold Th eir Health Expenditure to Sustainable Growth Rates. 16 Conclusion . 18 II. Why 35 Years of “Band-Aids” on a Fundamentally Flawed System Did Not Work. 21 Why One Popular Idea – the Consumer-Directed Health Plan – Will Not Work. 24 Consumer Direction . 24 High-Deductible Health Insurance. 24 Why Canada’s “Single-Payer” System or “Medical Care for All” Will Not Solve Our Health-Care Problems. -
A Work Project Presented As Part of the Requirements for the Award of a Master’S Degree In
A Work Project presented as part of the requirements for the Award of a Master’s degree in Finance from the Nova School of Business and Economics. THERANOS: BETTING ON BLOOD DIOGO JESUS NETO Work project carried out under the supervision of: Paulo Pinho 06-01-2020 Abstract Theranos was a Silicon Valley start-up founded by Elizabeth Holmes in 2003. Holmes claimed to have developed a new blood-testing device that had the potential to revolutionize the healthcare industry. She established partnerships with Walgreens and Safeway to make her technology available nationwide. She also secured a prestigious board of directors and an equally impressive investor base that raised over $700 million at a peak valuation of $9 billion. However, an investigation by The Wall Street Journal revealed the company had misled investors and endangered patients’ lives. In 2018, Theranos collapsed after years of battling lawsuits and federal charges. Keywords: Theranos, Corporate Governance, Fundraising, Due Diligence This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR Norte (Social Sciences DataLab, Project 22209). 1 Theranos: Betting on Blood “One of the most epic failures in corporate governance in the annals of American capitalism”. - John Carreyrou1 On June 28, 2019, a crowd of journalists awaited Elizabeth Holmes at the door of the San Jose Federal Court in California for a pre-trial hearing2. She was accused of engaging in a multi-million- dollar scheme to defraud investors, doctors, and patients alongside her former partner, Ramesh “Sunny” Balwani. -
Rethinking the Federal Securities Laws
Florida International University College of Law eCollections Faculty Publications Faculty Scholarship 2003 Accountants Make Miserable Policemen: Rethinking the Federal Securities Laws Jerry W. Markham Florida International University College of Law Follow this and additional works at: https://ecollections.law.fiu.edu/faculty_publications Part of the Banking and Finance Law Commons Recommended Citation Jerry W. Markham, Accountants Make Miserable Policemen: Rethinking the Federal Securities Laws, 28 N.C.J. Int'l L. & Com. Reg. 725, 812 (2003). This Article is brought to you for free and open access by the Faculty Scholarship at eCollections. It has been accepted for inclusion in Faculty Publications by an authorized administrator of eCollections. For more information, please contact [email protected]. +(,121/,1( Citation: Jerry W. Markham, Accountants Make Miserable Policemen: Rethinking the Federal Securities Laws, 28 N.C.J. Int'l L. & Com. Reg. 725 (2003) Provided by: FIU College of Law Content downloaded/printed from HeinOnline Tue May 1 11:26:02 2018 -- Your use of this HeinOnline PDF indicates your acceptance of HeinOnline's Terms and Conditions of the license agreement available at https://heinonline.org/HOL/License -- The search text of this PDF is generated from uncorrected OCR text. -- To obtain permission to use this article beyond the scope of your HeinOnline license, please use: Copyright Information Use QR Code reader to send PDF to your smartphone or tablet device Accountants Make Miserable Policemen: Rethinking the Federal -
BAD BLOOD John Carreyrou May 21St, 2018
BAD BLOOD John Carreyrou May 21st, 2018 OVERVIEW: In Bad Blood, Wall Street Journal reporter John Carreyrou details his investigation of Theranos, a former unicorn medical device company, exposing the company’s manipulation and outright fraud all seemed to overlook. - - - - - - - - - A UNICORN IS BORN: As Carreyrou describes, Elizabeth Holmes was well known for her fierce determination ingrained from an early age. Even before her teenage years had commenced, she declared her intention that she wanted to be a billionaire someday. Part of this motivation stemmed from her affluent and entrepreneurial family background. Impressed by her creativity and persistent drive, Holmes’ faculty mentor during college at Stanford – Channing Robertson – told her to “go out and pursue her dream.” That required advanced technology, yet Holmes’ scientific background consisted of a year at Stanford and an internship in a medical testing lab. Regardless, she conceived and patented the TheraPatch. Affixed to a patient’s arm, it would take blood painlessly through tiny needles, analyze the sample, and deliver a suitable drug dosage. Through her family connections into the venture capital world, she was able to raise $6 million from investors by the end of 2004, but it soon became clear that developing the patch was not possible. Undeterred, Holmes’ next idea was to have a patient prick a finger and put a drop of blood into a cartridge the size of a credit card though thicker. This would go into a “reader,” where pumps propelled the blood through a filter to hold back the red and white cells. The pumps would then push the remaining liquid plasma into wells where chemical reactions would provide the data to evaluate the sample. -
Eighteenth International Seapower Symposium: Report of the Proceedings
U.S. Naval War College U.S. Naval War College Digital Commons International Seapower Symposium Events 10-2007 Eighteenth International Seapower Symposium: Report of the Proceedings The U.S. Naval War College Follow this and additional works at: https://digital-commons.usnwc.edu/iss Recommended Citation Naval War College, The U.S., "Eighteenth International Seapower Symposium: Report of the Proceedings" (2007). International Seapower Symposium. 3. https://digital-commons.usnwc.edu/iss/3 This Book is brought to you for free and open access by the Events at U.S. Naval War College Digital Commons. It has been accepted for inclusion in International Seapower Symposium by an authorized administrator of U.S. Naval War College Digital Commons. For more information, please contact [email protected]. Color profile: Disabled Composite Default screen EIGHTEENTH INTERNATIONAL SEAPOWER SYMPOSIUM Report of the Proceedings ISS18.prn C:\Documents and Settings\john.lanzieri.ctr\Desktop\NavalWarCollege\5164_NWC_ISS-18\Ventura\ISS18.vp Friday, August 28, 2009 3:11:10 PM Color profile: Disabled Composite Default screen ISS18.prn C:\Documents and Settings\john.lanzieri.ctr\Desktop\NavalWarCollege\5164_NWC_ISS-18\Ventura\ISS18.vp Friday, August 28, 2009 3:11:12 PM Color profile: Disabled Composite Default screen EIGHTEENTH INTERNATIONAL SEAPOWER SYMPOSIUM Report of the Proceedings 17–19 October 2007 Edited by John B. Hattendorf Ernest J. King Professor of Maritime History Naval War College with John W. Kennedy NAVAL WAR COLLEGE NEWPORT,RHODE ISLAND -
Providing for the Common Defense (3/18/19)
Providing for the Common Defense (3/18/19) 00:00:25 Harmony Barker: Good evening and welcome. My name is Harmony Barker, and I'm the public programs coordinator here at the 9/11 Memorial & Museum. It's my pleasure to welcome all of you to tonight's program, "Providing for the Common Defense." As always, I'd like to extend a special welcome to our museum members and those turning in to our live web broadcast at 911memorial.org/live. 00:00:50 Tonight, we are joined by Admiral Gary Roughead and Ambassador Eric Edelman, co-chairs of the National Defense Strategy Commission, a congressionally chartered and nonpartisan body tasked with assessing the nation's defense strategy and military readiness. Admiral Roughead and Ambassador Edelman recently presented the Senate Armed Services Committee with the commission's report, "Providing for the Common Defense: "The Assessment and Recommendations of the National Defense Strategy Commission." 00:01:18 We are fortunate to have them both here to discuss their findings and to help us consider what U.S. national defense should look like in 2019. Gary Roughead graduated from the U.S. Naval Academy in 1973 and went on to have a distinguished naval career. He became the chief of naval operations in 2007, and is one of only two officers in the Navy's history to have commanded both the Atlantic and Pacific fleets. 00:01:46 Admiral Roughead has received the Defense Distinguished Service Medal, the Navy Distinguished Service Medal, Meritorious Service Medal, and Navy Commendation Medal, to name just a few of his decorations. -
The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market
University of Miami Business Law Review Volume 28 Issue 2 Article 8 September 2020 The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O'Brien Follow this and additional works at: https://repository.law.miami.edu/umblr Part of the Business Organizations Law Commons, and the Securities Law Commons Recommended Citation Theodore O'Brien, The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market, 28 U. Miami Bus. L. Rev. 404 (2020) Available at: https://repository.law.miami.edu/umblr/vol28/iss2/8 This Comment is brought to you for free and open access by the Journals at University of Miami School of Law Institutional Repository. It has been accepted for inclusion in University of Miami Business Law Review by an authorized editor of University of Miami School of Law Institutional Repository. For more information, please contact [email protected]. The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O’Brien* America’s securities laws and regulations, most of which were created in the early twentieth century, are increasingly irrelevant to the most dynamic emerging companies. Today, companies with sufficient investor interest can raise ample capital through private and exempt offerings, all while eschewing the public exchanges and the associated burdens of the initial public offering, public disclosures, and regulatory scrutiny. Airbnb, Inc., for example, quickly tapped private investors for $1 billion in April of 2020,1 adding to the estimated $4.4 billion the company had previously raised.2 The fundamental shift from public to private companies is evidenced by the so-called “unicorns,” the more than 400 private companies valued at more than $1 billion. -
Bad Blood Secrets and Lies in a Silicon Valley Startup by John Carreyrou
Bad Blood Secrets and Lies in a Silicon Valley Startup By John Carreyrou At its peak in 2013/14, Theranos had a valuation of $10 billion, representing incredible growth in the 10 years since its incorporation in 2003. The company claimed that it had developed and commercialized a revolutionary new blood testing solution. Viewed as a stunning start-up success, the Theranos board was a roster of well-known government and business leaders, including Henry Kissinger, James Mattis and Riley Bechtel. The buzz around Theranos was electric, and high-profile investors such as Betsey DeVos, the Walton family, and Rupert Murdoch invested hundreds of millions of dollars to fund the company. At the helm was Elizabeth Holmes, founder and CEO. Holmes dropped out of Stanford Engineering in 2004 and used her tuition fees to help fund her brainchild. Blond, attractive, and possessed of an unusually deep baritone voice, Holmes was listed by Forbes as one of America’s Richest Self-Made Women in 2015, with a net worth of over $4 billion. That same year, however, it all came crashing down when investigative reporter John Carreyrou of the Wall Street Journal revealed that the Theranos technology did not work as claimed. Carreyrou’s exhaustive research uncovered a web of lies and cover-ups, dating back to the earliest days at Theranos. Today, the company is worth nothing and has been dissolved, investors have lost multi- millions, and Elizabeth Holmes was charged with massive fraud by the SEC in March, 2018. This riches-to-rags story has captured the public’s imagination, and a movie based on Carreyrou’s book (starring Jennifer Lawrence as Elizabeth Holmes), is slated for release in 2020. -
How Innovation Works a Bright Future Not All Innovation Is Speeding up the Innovation Famine China’S Innovation Engine Regaining Momentum
Dedication For Felicity Bryan Contents Cover Title Page Dedication Introduction: The Infinite Improbability Drive 1. Energy Of heat, work and light What Watt wrought Thomas Edison and the invention business The ubiquitous turbine Nuclear power and the phenomenon of disinnovation Shale gas surprise The reign of fire 2. Public health Lady Mary’s dangerous obsession Pasteur’s chickens The chlorine gamble that paid off How Pearl and Grace never put a foot wrong Fleming’s luck The pursuit of polio Mud huts and malaria Tobacco and harm reduction 3. Transport The locomotive and its line Turning the screw Internal combustion’s comeback The tragedy and triumph of diesel The Wright stuff International rivalry and the jet engine Innovation in safety and cost 4. Food The tasty tuber How fertilizer fed the world Dwarfing genes from Japan Insect nemesis Gene editing gets crisper Land sparing versus land sharing 5. Low-technology innovation When numbers were new The water trap Crinkly tin conquers the Empire The container that changed trade Was wheeled baggage late? Novelty at the table The rise of the sharing economy 6. Communication and computing The first death of distance The miracle of wireless Who invented the computer? The ever-shrinking transistor The surprise of search engines and social media Machines that learn 7. Prehistoric innovation The first farmers The invention of the dog The (Stone Age) great leap forward The feast made possible by fire The ultimate innovation: life itself 8. Innovation’s essentials Innovation is gradual Innovation is different from invention Innovation is often serendipitous Innovation is recombinant Innovation involves trial and error Innovation is a team sport Innovation is inexorable Innovation’s hype cycle Innovation prefers fragmented governance Innovation increasingly means using fewer resources rather than more 9.